Maldonado J, Mansky L
Viruses. 2018; 10(7).
PMID: 30029500
PMC: 6070896.
DOI: 10.3390/v10070376.
Yasutake Y, Hattori S, Hayashi H, Matsuda K, Tamura N, Kohgo S
Sci Rep. 2018; 8(1):1624.
PMID: 29374261
PMC: 5785976.
DOI: 10.1038/s41598-018-19602-9.
Das K, Martinez S, Arnold E
Antimicrob Agents Chemother. 2017; 61(6).
PMID: 28396546
PMC: 5444136.
DOI: 10.1128/AAC.00224-17.
Connell B, Chang S, Prakash E, Yousfi R, Mohan V, Posch W
PLoS One. 2016; 11(10):e0165386.
PMID: 27788205
PMC: 5082894.
DOI: 10.1371/journal.pone.0165386.
Miyamoto F, Kawaji K, Oishi S, Fujii N, Kaku M, Kodama E
Antivir Chem Chemother. 2015; 24(2):77-82.
PMID: 26527820
PMC: 5890520.
DOI: 10.1177/2040206615614164.
Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010-2011.
Liu J, Wu Y, Yang W, Xue X, Sun G, Liu C
AIDS Res Ther. 2015; 12:22.
PMID: 26120348
PMC: 4483220.
DOI: 10.1186/s12981-015-0062-y.
Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
Aoki M, Danish M, Aoki-Ogata H, Amano M, Ide K, Das D
J Virol. 2012; 86(24):13384-96.
PMID: 23015723
PMC: 3503118.
DOI: 10.1128/JVI.07234-11.
HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.
Boyer P, Clark P, Hughes S
J Virol. 2012; 86(10):5885-94.
PMID: 22438533
PMC: 3347278.
DOI: 10.1128/JVI.06597-11.
Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.
Jegede O, Khodyakova A, Chernov M, Weber J, Menendez-Arias L, Gudkov A
Antiviral Res. 2011; 91(2):94-8.
PMID: 21600931
PMC: 3144253.
DOI: 10.1016/j.antiviral.2011.05.004.
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.
Mbisa J, Gupta R, Kabamba D, Mulenga V, Kalumbi M, Chintu C
Retrovirology. 2011; 8:31.
PMID: 21569325
PMC: 3113953.
DOI: 10.1186/1742-4690-8-31.
Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1.
Martinez J, Bocharov G, Ignatovich A, Reiter J, Dittmar M, Wain-Hobson S
PLoS One. 2011; 6(3):e18375.
PMID: 21483787
PMC: 3069090.
DOI: 10.1371/journal.pone.0018375.
Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase.
Scarth B, White K, Chen J, Lansdon E, Swaminathan S, Miller M
Antimicrob Agents Chemother. 2011; 55(6):2662-9.
PMID: 21402840
PMC: 3101450.
DOI: 10.1128/AAC.01738-10.
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.
Hachiya A, Kodama E, Schuckmann M, Kirby K, Michailidis E, Sakagami Y
PLoS One. 2011; 6(1):e16242.
PMID: 21249155
PMC: 3020970.
DOI: 10.1371/journal.pone.0016242.
Impaired replication capacity of acute/early viruses in persons who become HIV controllers.
Miura T, Brumme Z, Brockman M, Rosato P, Sela J, Brumme C
J Virol. 2010; 84(15):7581-91.
PMID: 20504921
PMC: 2897600.
DOI: 10.1128/JVI.00286-10.
Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.
Matamoros T, Nevot M, Martinez M, Menendez-Arias L
J Biol Chem. 2009; 284(47):32792-802.
PMID: 19801659
PMC: 2781696.
DOI: 10.1074/jbc.M109.038885.
Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene.
Kowalski J, Gange S, Schneider M, Tsai H, Templeton A, Shao Q
J Acquir Immune Defic Syndr. 2009; 50(4):381-9.
PMID: 19214121
PMC: 2937199.
DOI: 10.1097/QAI.0b013e318198a619.
Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S
J Biol Chem. 2008; 284(8):4914-20.
PMID: 19073606
PMC: 2643509.
DOI: 10.1074/jbc.M807169200.
Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain.
McConnell M, Docobo-Perez F, Mata R, Fernandez-Cuenca F, Viciana P, Lopez-Cortes L
AIDS Res Hum Retroviruses. 2008; 24(6):881-7.
PMID: 18572440
PMC: 2927033.
DOI: 10.1089/aid.2008.0051.
Clinical significance of human immunodeficiency virus type 1 replication fitness.
Dykes C, Demeter L
Clin Microbiol Rev. 2007; 20(4):550-78.
PMID: 17934074
PMC: 2176046.
DOI: 10.1128/CMR.00017-07.
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
Cong M, Heneine W, Garcia-Lerma J
J Virol. 2006; 81(6):3037-41.
PMID: 17192300
PMC: 1865994.
DOI: 10.1128/JVI.02712-06.